Showing 4361-4370 of 9117 results for "".
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Dermavant Publishes ADORING 1 & ADORING 2 Phase 3 Trial Results for Vtama Cream for ADhttps://practicaldermatology.com/news/dermavant-publishes-adoring-1-adoring-2-phase-3-trial-results-vtama-cream-ad/2463173/Dermavant Sciences announced that the data from ADORING 1 and ADORING 2 phase 3 trials of Vtama (tapinarof) cream 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology. Vtama cream i
- A New, Proactive Approach to Newborn Skincarehttps://practicaldermatology.com/news/new-proactive-approach-newborn-skincare/2463138/Aveeno Baby announced the launch of Healthy Start, a proactive approach to newborn skincare featuring a wash and balm duo that are safe to use on newborn skin from birth. Aveeno Baby Healthy Start Newborn Wash is a nourishing cleanser made with prebiotic oat, oat extract, and glycerin to
- Reflections on the “Clearly Me” Psoriasis Exhibithttps://practicaldermatology.com/news/reflecting-on-clearly-me-psoriasis-exhibit-a-qa-with-lindsay-adler/2463137/The “Clearly Me” exhibit in New York, New York, held from May 16-18, showcased real psoriatic patients through dynamic photographic portraits, captured by photographer L
- Research IDs New Psoriasis Inflammation Pathwayhttps://practicaldermatology.com/news/research-ids-new-psoriasis-inflammation-pathway/2463125/Researchers from a recent study have identified a key biological pathway responsible for the inflammation seen in psoriasis, with potential implications for other inflammatory diseases like atopic dermatitis, allergic dermatitis, and hidradenitis suppurativa. The study, published in the j
- Survey Shows Variability in Hyaluronidase Use Among Practitionershttps://practicaldermatology.com/news/survey-shows-variability-hyaluronidase-use-among-practitioners/2463109/New research suggests there are inconsistencies in the use of hyaluronidase (HYAL) for the treatment of adverse events with hyaluronic acid (HA) fillers, suggesting a need for standardized guidelines. "With the growing popularity and administration of HA fillers, there is likely to be a c
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the e
- Johnson & Johnson Acquires Proteologix, Maker of Atopic Dermatitis Candidate, for $850 Millionhttps://practicaldermatology.com/news/johnson-johnson-acquires-proteologix-maker-atopic-dermatitis-candidate-850-million/2463090/Johnson & Johnson has entered into a definitive agreement to acquire biotech company Proteologix for $850 million in cash, with potential for an additional milestone payment. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to ente
- Pilot Study Supports Once-Daily Isotretinoin for Acne Treatmenthttps://practicaldermatology.com/news/pilot-study-supports-once-daily-isotretinoin-acne-treatment/2463088/Micronized isotretinoin administered once per day without food was effective and well-tolerated for the treatment of severe nodular acne, new study results indicate. Researchers for the pilot study focused on and evaluated a regimen of once-daily micronized isotretinoin (0.4 to 0.8 mg/kg/
- Study: Apremilast Efficacy Shows Efficacy in Psoriasishttps://practicaldermatology.com/news/study-apremilast-efficacy-shows-efficacy-psoriasis/2463053/Results from a recent analysis suggest promise for apremilast, which showed efficacy in the treatment of patients with moderate-to-severe psoriasis. Authors publishing in Acta Dermato-Venereologica focused on the impact on skin lesions, pruritus, and serum cytokine levels. The r